Thyroid Nodules with Indeterminate FNAC According to the Italian Classification System: Prevalence, Rate of Operation, and Impact on Risk of Malignancy. An Updated Systematic Review and Meta-analysis.
Carcinoma
Fine-needle aspiration (FNAC)
Indeterminate nodules
Italian Consensus for the Classification and Reporting of Thyroid Cytology
Risk of malignancy
Thyroid
Journal
Endocrine pathology
ISSN: 1559-0097
Titre abrégé: Endocr Pathol
Pays: United States
ID NLM: 9009288
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
accepted:
16
08
2022
pubmed:
1
9
2022
medline:
3
12
2022
entrez:
31
8
2022
Statut:
ppublish
Résumé
A thyroid nodule classified as indeterminate on fine-needle aspiration cytology (FNAC), hereafter referred to as an indeterminate thyroid nodule (ITN), represents a clinical dilemma. The Italian Consensus for the Classification and Reporting of Thyroid Cytology (ICCRTC) divides ITNs into low- and high-risk categories (i.e., TIR3A and TIR3B, respectively) to better manage patients. This study aimed to achieve high-evidence estimates of the prevalence, rate of operation, and risk of malignancy of ITNs, including TIR3A and TIR3B ITNs. This systematic review was conducted according to MOOSE to retrieve all original studies citing ICCRTC. The last search was performed in February 2022. The risk of bias of the included studies was assessed. Separate proportion meta-analyses were performed with a random-effect model using OpenMeta[Analyst]. The online search processed 271 studies, and 33 were finally considered. First, the cancer prevalence among ITNs was 32.4%. Second, the cancer prevalence among TIR3As was 12.4%, with heterogeneity (I
Identifiants
pubmed: 36044162
doi: 10.1007/s12022-022-09729-x
pii: 10.1007/s12022-022-09729-x
pmc: PMC9712406
doi:
Types de publication
Systematic Review
Meta-Analysis
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
457-471Informations de copyright
© 2022. The Author(s).
Références
Cytopathology. 2017 Dec;28(6):503-508
pubmed: 28913847
Pathologica. 2010 Oct;102(5):405-8
pubmed: 21361121
Thyroid. 2009 Nov;19(11):1159-65
pubmed: 19888858
Int J Endocrinol. 2020 Apr 14;2020:7325260
pubmed: 32351561
Diagn Cytopathol. 2002 Jan;26(1):41-4
pubmed: 11782086
Radiol Med. 2021 Sep;126(9):1189-1200
pubmed: 34129178
Clin Endocrinol (Oxf). 2019 Dec;91(6):851-859
pubmed: 31483883
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Front Endocrinol (Lausanne). 2017 Oct 16;8:273
pubmed: 29085338
Endocrine. 2018 Apr;60(1):31-35
pubmed: 28786076
Thyroid. 2019 Feb;29(2):222-228
pubmed: 30426887
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Cytopathology. 2019 Sep;30(5):460-467
pubmed: 30875124
J Endocrinol Invest. 2010;33(5 Suppl):1-50
pubmed: 20543550
Endocrine. 2020 May;68(2):458-465
pubmed: 32232767
Cancer Cytopathol. 2015 Dec;123(12):713-22
pubmed: 26355876
Front Endocrinol (Lausanne). 2018 Jul 10;9:371
pubmed: 30050499
Thyroid. 2020 Jan;30(1):65-71
pubmed: 31552809
Endocrine. 2016 Apr;52(1):39-45
pubmed: 26142180
Endocrine. 2016 Dec;54(3):723-732
pubmed: 26818914
Cytopathology. 2021 Nov;32(6):714-717
pubmed: 34050989
Horm Metab Res. 2019 Sep;51(9):559-567
pubmed: 31505702
J Endocrinol Invest. 2021 Jul;44(7):1343-1351
pubmed: 33590467
Int J Surg. 2017 May;41 Suppl 1:S60-S64
pubmed: 28506415
Cancer Cytopathol. 2020 Apr;128(4):250-259
pubmed: 31899594
Front Endocrinol (Lausanne). 2021 Feb 24;12:613727
pubmed: 33716969
Metabolomics. 2018 Oct 10;14(10):141
pubmed: 30830426
Endocrine. 2017 Aug;57(2):256-261
pubmed: 27804016
JAMA. 2018 Mar 06;319(9):914-924
pubmed: 29509871
J Endocrinol Invest. 2014 Jun;37(6):593-9
pubmed: 24789536
JAMA Oncol. 2016 Aug 1;2(8):1023-9
pubmed: 27078145
Eur Thyroid J. 2017 Apr;6(2):94-100
pubmed: 28589091
Thyroid. 2018 Feb;28(2):210-219
pubmed: 29160163
Int J Endocrinol. 2020 Apr 21;2020:7543930
pubmed: 32377187
Endocrine. 2020 Sep;69(3):553-561
pubmed: 32124261
J Endocrinol Invest. 2014 Oct;37(10):1009-14
pubmed: 25194426
Clin Endocrinol (Oxf). 2014 Jul;81 Suppl 1:1-122
pubmed: 24989897
J Endocrinol Invest. 2021 Apr;44(4):803-809
pubmed: 32797379
Cancer Cytopathol. 2020 Jan;128(1):36-42
pubmed: 31722134
Cancers (Basel). 2021 Feb 22;13(4):
pubmed: 33671494
Endocrine. 2021 Jun;72(3):711-720
pubmed: 33030666
Endocrine. 2021 May;72(2):486-494
pubmed: 33006725
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
J Endocrinol Invest. 2019 Jan;42(1):1-6
pubmed: 29546655
J Biol Regul Homeost Agents. 2016 Oct-Dec;30(4):1187-1193
pubmed: 28078873
Cancer Cytopathol. 2020 Apr;128(4):238-249
pubmed: 31883438
J Endocrinol Invest. 2018 May;41(5):531-538
pubmed: 28948534
Int J Endocrinol. 2017;2017:9692304
pubmed: 28348589
Cancers (Basel). 2021 May 06;13(9):
pubmed: 34066485
Eur J Endocrinol. 2018 Jun;178(6):595-603
pubmed: 29626008
Endocr Pathol. 2018 Mar;29(1):75-79
pubmed: 29396808